Teacher Retirement System of Texas acquired a new position in Haemonetics Corporation (NYSE:HAE - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 7,351 shares of the medical instruments supplier's stock, valued at approximately $467,000.
Other large investors have also added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Haemonetics by 10.7% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 12,460 shares of the medical instruments supplier's stock valued at $973,000 after buying an additional 1,202 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Haemonetics by 7.8% in the 4th quarter. HighTower Advisors LLC now owns 3,353 shares of the medical instruments supplier's stock valued at $262,000 after acquiring an additional 244 shares in the last quarter. Swiss National Bank increased its position in shares of Haemonetics by 1.2% in the fourth quarter. Swiss National Bank now owns 100,700 shares of the medical instruments supplier's stock valued at $7,863,000 after acquiring an additional 1,200 shares during the last quarter. Natixis Advisors LLC bought a new stake in Haemonetics during the fourth quarter worth about $1,194,000. Finally, Cibc World Markets Corp acquired a new position in Haemonetics during the fourth quarter valued at approximately $367,000. Institutional investors and hedge funds own 99.67% of the company's stock.
Haemonetics Stock Performance
Shares of HAE stock opened at $74.46 on Thursday. Haemonetics Corporation has a 52 week low of $55.30 and a 52 week high of $94.99. The company has a market capitalization of $3.58 billion, a price-to-earnings ratio of 22.49, a PEG ratio of 1.21 and a beta of 0.39. The company has a 50-day simple moving average of $71.44 and a 200 day simple moving average of $67.99. The company has a debt-to-equity ratio of 1.12, a quick ratio of 0.99 and a current ratio of 1.62.
Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The medical instruments supplier reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.22 by $0.02. Haemonetics had a net margin of 12.32% and a return on equity of 26.37%. The firm had revenue of $330.60 million during the quarter, compared to the consensus estimate of $329.38 million. During the same period last year, the business posted $0.90 earnings per share. The business's revenue for the quarter was down 3.5% compared to the same quarter last year. On average, sell-side analysts predict that Haemonetics Corporation will post 4.55 earnings per share for the current year.
Analyst Ratings Changes
Several research analysts have weighed in on HAE shares. Barrington Research reaffirmed an "outperform" rating and set a $95.00 price target on shares of Haemonetics in a research report on Friday, July 11th. Wall Street Zen downgraded shares of Haemonetics from a "buy" rating to a "hold" rating in a report on Tuesday, May 13th. Citigroup raised shares of Haemonetics from a "neutral" rating to a "buy" rating and set a $90.00 price target on the stock in a research report on Wednesday, July 9th. Robert W. Baird started coverage on shares of Haemonetics in a research report on Thursday, June 26th. They issued an "outperform" rating and a $87.00 price objective for the company. Finally, Raymond James Financial reaffirmed a "strong-buy" rating and issued a $105.00 target price (down from $115.00) on shares of Haemonetics in a report on Friday, May 9th. One analyst has rated the stock with a sell rating, one has given a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $97.30.
Read Our Latest Research Report on HAE
Haemonetics Company Profile
(
Free Report)
Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Haemonetics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Haemonetics wasn't on the list.
While Haemonetics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
